Spots Global Cancer Trial Database for Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Official Title: Phase I/II Study of the Combination of Irinotecan and POF (Paclitaxel Plus Oxaliplatin Plus 5-fluorouracil Plus Leucovorin) and Tislelizumab

Study ID: NCT05319639

Conditions

Gastric Cancer Stage IV

Interventions

Study Description

Brief Summary: The purpose of the phase I/II study is to establish the safety of Combination of Irinotecan and paclitaxel with 5-FU, leucovorin, oxaliplatin and Tislelizumab.

Detailed Description:

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Fujian cancer hospital, Fuzhou, Fujian, China

Contact Details

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: